Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ending September 29, 2023. The report serves to lodge the Company's annual statutory financial statements for the financial year ended June 30, 2023, with the Australian Securities and Investments Commission (ASIC).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibit 99.1 (Statutory Financial Statements), which is referenced but not detailed in the body of this report.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document acts solely as a cover for the submission of the full annual statutory statements.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or unusual items. No specific operational updates are included in this summary document.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 for the actual financial data for the year ended June 30, 2023.
- Confirm the filing date of September 29, 2023, aligns with the lodgement of Australian statutory requirements.